Refining megatherapy, improving outcome in neuroblastoma
Mené sur 598 patients atteints d'un neuroblastome à haut risque de récidive, cet essai de phase III compare l'efficacité, du point de vue de la survie sans événement à 3 ans, et la toxicité de deux chimiothérapies à hautes doses, l'une à base de busulfan et melphalan, l'autre combinant carboplatine, étoposide et melphalan
Neuroblastoma is a major cause of paediatric cancer mortality and is clinically and biologically heterogeneous. Over 30 years ago, amplification of the MYCN oncogene was shown to be associated with aggressive disease.1 Currently, disease risk is assessed and treatment selected based on MYCN amplification and other biological features. In parallel with the refinement in risk assignment, treatment has substantially improved by use of multimodality approaches. Over the past 20 years, 5-year overall survival for children with high-risk neuroblastoma has increased from 29% to 50%.
The Lancet Oncology , commentaire, 2016